Jack Wallace
Stock Analyst at Guggenheim
(3.13)
# 1,184
Out of 4,711 analysts
22
Total ratings
57.89%
Success rate
10.79%
Average return
Main Sectors:
Stocks Rated by Jack Wallace
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Buy | $233 → $249 | $224.15 | +11.09% | 4 | Oct 1, 2024 | |
| WW WW International | Maintains: Buy | $12 → $6 | $1.34 | +347.76% | 3 | Aug 2, 2024 | |
| HIMS Hims & Hers Health | Maintains: Buy | $15 → $17 | $26.20 | -35.11% | 4 | Feb 27, 2024 | |
| HCAT Health Catalyst | Upgrades: Buy | $14 | $7.09 | +97.46% | 3 | Jan 26, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $253 → $220 | $197.27 | +11.52% | 1 | Nov 3, 2023 | |
| PHR Phreesia | Maintains: Buy | $35 → $40 | $25.16 | +58.98% | 5 | Mar 29, 2023 | |
| AMWL American Well | Reiterates: Buy | $100 | $7.87 | +1,170.65% | 1 | Mar 15, 2023 | |
| PINC Premier | Initiates: Neutral | n/a | $21.76 | - | 1 | Apr 14, 2022 |
Veeva Systems
Oct 1, 2024
Maintains: Buy
Price Target: $233 → $249
Current: $224.15
Upside: +11.09%
WW International
Aug 2, 2024
Maintains: Buy
Price Target: $12 → $6
Current: $1.34
Upside: +347.76%
Hims & Hers Health
Feb 27, 2024
Maintains: Buy
Price Target: $15 → $17
Current: $26.20
Upside: -35.11%
Health Catalyst
Jan 26, 2024
Upgrades: Buy
Price Target: $14
Current: $7.09
Upside: +97.46%
IQVIA Holdings
Nov 3, 2023
Maintains: Buy
Price Target: $253 → $220
Current: $197.27
Upside: +11.52%
Phreesia
Mar 29, 2023
Maintains: Buy
Price Target: $35 → $40
Current: $25.16
Upside: +58.98%
American Well
Mar 15, 2023
Reiterates: Buy
Price Target: $100
Current: $7.87
Upside: +1,170.65%
Premier
Apr 14, 2022
Initiates: Neutral
Price Target: n/a
Current: $21.76
Upside: -